<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (TRAIL) is a potent inducer of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in sensitive cells and may be suitable for novel anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies aimed at inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> via the activation of TRAIL receptors on malignant cells </plain></SENT>
<SENT sid="1" pm="."><plain>Here we have characterized the TRAIL sensitivity of a panel of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>Overall, 5/12 BL cell lines and 1/2 lymphoblastoid cell lines were sensitive to TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, although only one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line approached the sensitivity of Jurkat cells, a widely used model for TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Whereas, 4/5 of the Epstein-Barr virus (EBV)-negative cell lines were TRAIL sensitive, only 1/7 EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines were TRAIL sensitive </plain></SENT>
<SENT sid="4" pm="."><plain>However, isogenic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines with different EBV status were not differently sensitive to TRAIL, indicating that EBV is not a major determinant of TRAIL sensitivity </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cell lines expressed the <z:hpo ids='HP_0011420'>death</z:hpo> receptor (DR)5 TRAIL receptor, whereas expression of DR4 was more variable </plain></SENT>
<SENT sid="6" pm="."><plain>Differences in the expression of downstream signalling molecules [Fas-associated <z:hpo ids='HP_0011420'>death</z:hpo> domain protein (FADD), caspase 8] and inhibitors [decoy receptor 1 (DcR1), cellular FLICE-like inhibitory protein (c-FLIP)] did not correlate with TRAIL sensitivity </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, a subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines are sensitive to TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, however, the molecular mechanism that determines responsiveness remains to be identified </plain></SENT>
</text></document>